Market cap
$243 Mln
Market cap
$243 Mln
Revenue (TTM)
$19 Mln
P/E Ratio
--
P/B Ratio
10.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0
Book Value
$7.6
EPS
$-2
Face value
--
Shares outstanding
3,245,270
CFO
$-161.57 Mln
EBITDA
$-189.75 Mln
Net Profit
$-187.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sol-Gel Technologies - ADR
| 69.4 | -9.8 | 12.4 | 739.0 | 25.8 | -8.7 | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Sol-Gel Technologies - ADR
| 353.1 | -75.8 | -38.4 | -24.4 | -42.9 | 184.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sol-Gel Technologies - ADR
|
71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 |
| 0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 | |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 | |
| 0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 | |
| 0.5 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 | |
| 23.2 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The... company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Read more
Co-Founder, CEO & Director
Dr. Alon Seri-Levy
Co-Founder, CEO & Director
Dr. Alon Seri-Levy
Headquarters
Ness Ziona
Website
The share price of Sol-Gel Technologies Ltd - ADR is $71.40 (NASDAQ) as of 30-Apr-2026 10:25 EDT. Sol-Gel Technologies Ltd - ADR has given a return of 25.76% in the last 3 years.
Since, TTM earnings of Sol-Gel Technologies Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-20.63
|
5.54
|
|
2024
|
-0.26
|
0.10
|
|
2023
|
-0.12
|
0.09
|
|
2022
|
-0.61
|
0.22
|
|
2021
|
4.59
|
0.27
|
The 52-week high and low of Sol-Gel Technologies Ltd - ADR are Rs 97.97 and Rs 4.11 as of 30-Apr-2026.
Sol-Gel Technologies Ltd - ADR has a market capitalisation of $ 243 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sol-Gel Technologies Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.